The monoclonal antibody SZ1 is of interest for two reasons: it was used to define complex formation between glycoprotein (GP) Ib and GP IX, and its epitope is likely to be identical to that recognized by most quinine-and quinidine-dependent autoantibodies that cause thrombocytopenia. To determine the location of the epitope for SZ1 within the GP Ib-IX complex (which consists of three subunits: GP Iba, GP Ibp, and GP 1x1, we tested the ability of the antibody to bind transfected cells that expressed different combinations of complex subunits, and compared this binding to the binding of antibodies of known specificity. SZ1 bound to cells that expressed the entire GP Ib-IX complex in the same pattern as did AN51 (an antibody specific for GP Iba). However, unlike AN51, SZ1 did not bind ap cells (ie, cells that express GP HE PLATELET MEMBRANE glycoprotein (GP) Ib-IX complex mediates two adhesive processes of vital importance in hemostasis and thrombosis: platelet adhesion to the blood vessel wall at sites of injury, and shear-induced platelet aggregation. The complex is also necessary for platelet aggregation induced by low concentrations of thrombin.' The first two processes are accomplished by the binding of the complex to von Willebrand factor (vWf); in the first case, with vWf attached to the vessel subendothelial matrix,* and in the second, with vWf in the plasma. ' Three polypeptides make up the GP Ib-IX complex: the two subunits of GP Ib-GP Iba and GP Ibp-and GP IX. Each subunit is encoded by its own gene4-' and associates with the others after synthesis. The binding sites for vWf and thrombin reside on the largest of the three polypeptides, GP Iba.' GP Iba is linked by a disulfide bond to GP Ibp; GP IX associates noncovalently. The three polypeptides arose from a common ancestor and are members of a protein family characterized by a leucine-rich motif?. ' The three GP Ib-IX subunits are necessary for efficient expression of a functional complex on the plasma membrane,7 and are expressed there in equimolar stoichiometry.x Much of the evidence that GP Ib and GP IX exist as a complex on the platelet plasma membrane comes from work with the monoclonal antibody SZ1, which was raised by immunizing mice with whole human platelets.' Du et ai9 showed that this antibody immunoprecipitated intact purified GP Ib-IX complex, but not GP Ib or GP IX alone. Reconstituting the complex by combining the two components also reconstituted the epitope for SZ1, which led to the conclusion that the epitope was complex-specific. The number of sites for SZ1 on the platelet surface was similar to the number of sites for several GP Ib antibodies. In our laboratory, we used SZ1 to demonstrate that a complex formed between GP Ib and GP IX when the three complex subunits were cotransfected into heterologous cells.'
Iba and GP Ibp, but not GP 1x1, but did bind to PIX and alX cells. We then compared the binding patterns of SZ1 and FMC25, an antibody specific for GP IX. Both bound virtually identically to cell lines that expressed every combination of two of the three GP Ib-IX complex subunits. However, the epitopes of the two antibodies were not identical, because fixation with 4% paraformaldehyde of cells that expressed GP IX destroyed the SZ1 epitope while maintaining the FMC25 epitope. Because of the ability of SZ1 to block the binding of many quinine-and quinidine-dependent antibodies, these data strongly suggest that GP IX is the component of the GP Ib-IX complex recognized by those antibodies. 0 1995 by The American Society of Hematology.
showed that this antibody immunoprecipitated intact purified GP Ib-IX complex, but not GP Ib or GP IX alone. Reconstituting the complex by combining the two components also reconstituted the epitope for SZ1, which led to the conclusion that the epitope was complex-specific. The number of sites for SZ1 on the platelet surface was similar to the number of sites for several GP Ib antibodies. In our laboratory, we used SZ1 to demonstrate that a complex formed between GP Ib and GP IX when the three complex subunits were cotransfected into heterologous cells. ' The SZ1 monoclonal antibody is of interest not only because it recognizes an epitope whose conformation may require the full complex for its formation, but also because it recognizes the most common epitope of antibodies that cause thrombocytopenia in patients treated with quinine or its stereoisomer, quinidine. The majority of drug-dependent antibodies that cause thrombocytopenia in patients who take these medications have been shown to recognize an epitope on the GP Ib-IX c o m p l e~. '~"~ That epitope appears to be identical, or very close, to the SZ1 epitope, because SZ1 completely blocked binding of 1 1 of 12 drug-dependent sera examined by Chong et al. '' In the current report, we used transfected cells that expressed different combinations of GP Ib-IX subunits to demonstrate that SZ1 recognizes an epitope on GP IX that does not require the other subunits for its expression. We also demonstrate, in agreement with previous results," that this epitope is dependent on polypeptide conformation-it is destroyed by fixing the cells with 4% paraformaldehyde.
MATERIALS AND METHODS
Monoclonal antibodies. S 2 1 (IgG2,) and AN51 (IgGd were both purchased from DAKO (Carpinteria, CA were first selected for plasmid incorporation by growth in the neomycin analog G418 (400 pg/mL). To increase the copy number of the transfected plasmids and simultaneously to select for the second plasmid, (3418-resistant cells were grown in successively higher concentrations of methotrexate, beginning at 5 nmoVL and doubling the concentration every 2 weeks until it reached 80 pmolfL.
Transient transfections of COS-7 cells were performed by the DEAE-dextran method,I6 and of C H 0 cells by liposome-mediated DNA transfer using a commercial kit (LipofectAMINE; BRL Life Technologies, Grand Island, NY). For liposome-mediated transfer, 6 pL of liposome suspension and 1 or 2 pg of DNA were separately mixed in 100 pL of serum-free medium. The two suspensions were then combined and mixed gently, and incubated for 30 minutes at room temperature to form DNAAiposome complexes. The mixture was diluted in 0.8 mL of serum-free medium and added to cells that had been washed twice with the same medium. The cells were exposed to the DNMiposome mixture for 5 hours under standard culture conditions (37"C, 5% CO,), after which time an additional 1 mL of medium containing 10% fetal bovine serum was added. The medium was changed 24 hours later. Forty-eight hours after transfection, the cells were detached from the culture dishes with 0.54 m m o K of EDTA and evaluated by flow cytometry for surface expression of the SZ1 epitope.
Flow cyfometry. Flow cytometry was performed on a Becton Dickinson FACScan or a Becton Dickinson FACS 440 (Becton Dickinson, San Jose, CA). Before analysis, cells were detached from tissue culture flasks with 0.54 mmoVL of EDTA, then labeled with either fluorescein isothiocyanate (F1TC)-conjugated primary antibodies or unlabeled primary antibodies followed by FITC-conjugated goat antimouse secondary antibodies (Zymed, South San Francisco, CA). When two antibodies were used (indirect immunofluorescence), the cells were incubated with the primary antibody (5 ,ug/mL) at room temperature for 30 minutes, washed twice by resuspension in phosphate-buffered saline (PBS), incubated for 30 minutes in a 1:1,OOO dilution of the secondary antibody, and washed again. The cells were then resuspended in 0.5 mL of tissue culture medium and kept in the dark and on ice until analyses were performed.
Fluorescence microscopy.
Cells were grown directly on glass chamber slides (Titertek Nunc, Naperville, IL), washed with PBS, fixed in 4% paraformaldehyde, and permeabilized with 0.1 % Triton X-100. They were then incubated for 60 minutes with the primary monoclonal antibody (either SZ1 or FMC2.5) at a concentration of 5 pg/mL, washed twice with PBS, and incubated in a 1:250 dilution of biotinylated goat antimouse antibodies (Amersham, Arlington Heights, IL) for 30 minutes and a 1:1,000 dilution of FITC-conjugated streptavidin (Amersham; RPN 1232) for 30 minutes. The cells were then visualized with a Zeiss fluorescence microscope.
RESULTS
Three subunits of the GP Ib-IX complex are not necessary for expression of the SZI epitope. The epitope for the monoclonal antibody SZ1 requires formation of a complex between GP Ib and GP IX when the purified components of the complex are in detergent solution.' It is now possible to study the requirements for this epitope in living cells by expressing the cDNAs that encode the three complex subunits. We therefore studied the binding of SZ1 to both stably and transiently transfected cells that express different combinations of GP Ib-IX complex subunits. Our previous work demonstrated that the three complex subunits were required for efficient expression of the ligand-binding subunit, GP Iba, on the plasma membranes of transfected cells,' which raised the possibility that transfection of less than the full complement of subunits would result in plasma membrane expression at levels insufficient for study. To avert this problem, we used a dihydrofolate-reductase-based amplification strategy to enhance expression of the transfected polypeptides, which we expected also would increase their expression on the cell surface. Figure 1 shows the results of flow cytometry of CH0 cells that expressed either the entire complex (CH0 aPIX cells) or only GP Iba and GP IbyP (CH0 ayP cells). Binding of SZ1 was compared with that of AN51, which has an epitope on GP Iba.13 When CH0 aPIX cells were evaluated, both antibodies bound to the same number of cells and at similar levels per cell, which indicates that the same number of epitopes for the two antibodies were expressed in this cell line (Fig l, upper panels) . In contrast, although AN51 did not bind to CH0 PIX cells, the entire population was positive when reacted with SZ1 (Fig l , lower panels) . The opposite pattern was observed when C H 0 ayP cells were tested: AN5 1 recognized a positive cell population and SZ1 was completely negative (Fig 2) . required GP IX for its proper conformation. Therefore, we compared the pattern of SZl reactivity with that of an antibody of known specificity for GP IX, FMC25." The two antibodies had similar patterns of reactivity when tested simultaneously in C H 0 aPIX, C H 0 aIX, and C H 0 PIX cells (Fig 3) , which provides evidence that SZ1 recognized GP IX. The binding of SZ1 to C H 0 aIX cells and its failure to bind to C H 0 a0 cells establishes with virtual certainty that the epitope resides on GP IX.
The SZI epitope is destroyed by fixing cells with 4% paraformaldehyde. As a complement to the flow-cytometry studies, we used immunofluorescence to compare SZ1 binding with M C 2 5 binding in cells fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Although FMC25 gave a strong fluorescent signal, SZ1 was now completely unreactive (Fig 4) . The epitope recognized by FMC25 was maintained, while that of SZ1 was undetectable, even in nonpermeabilized cells, which indicates that the SZ1 epitope either is very sensitive to conformational changes or is destroyed directly on fixation by covalent modification of a critical residue.
DISCUSSION
One way that GP Ib and GP IX were shown to exist on the plasma membrane in a noncovalent complex was with the murine monoclonal antibody SZl.9 This observation helped to explain two phenomena: the lack of both proteins from the surfaces of platelets in most cases of the BernardSoulier syndrome," and the requirement for the three subunits of the GP Ib-IX complex for efficient complex expression on the surfaces of transfected cells. ' Defining the exact site of the SZ1 epitope has been problematic. It was known only to require both GP Ib and GP LOPEZ ET AL IX, based on examination of binding to the purified proteins.'
The possibility that SZ1 bound to a site on GP IX proximal to the FMC25 epitope was suggested by the results of crossblocking experiments using the two antibodies.
With the availability of the cDNAs that encode these subunits, it has now become possible to study the SZ1 epitope within the plasma membranes of living cells by expressing the complex subunits in different combinations. The current study shows that the SZ1 epitope is located on GP IX and provides an explanation for the requirement of an intact complex when detergent-solubilized polypeptides were examined: the epitope's conformational sensitivity. The epitope may be destroyed by the detergents necessary to solubilize GP Ib and GP IX. Simply fixing cells with paraformaldehyde was enough to destroy the epitope, although that of the anti-GP IX monoclonal antibody FMC25 (which showed an identical pattern of reactivity by flow cytometry) was unaffected.
When cells that express every combination of two subunits were examined for their reactivity with SZ1, only those that expressed GP IX bound the antibody; cells that expressed only GP Iba and GP IbP did not. The binding of SZ1 to cells that expressed GP IbP and GP IX, but not GP Iba, is definitive evidence that the SZ1 epitope is not on GP Iba and does not depend on GP lbcr for its expression. Lack of reactivity with cells that expressed the two subunits of GP lb. but not GP IX, provided evidence that the epitope resides on GP IX. However, the possibility that it might be on GP Ibp is not completely excluded by these data. That conclusion required evidence that the antibody would bind to cells that did not contain GP Ibp. This evidence was provided by the demonstration that the antibody bound cells that stably expressed only GP lba and GP IX. Whether the epitope requires an association between GP IX and either of the two GP Ib subunits is a question not directly answered by the data here. However, two lines of evidence suggest that such an association is not required for epitope formation. First, when SZI reactivity was compared with that of FMC25, an antibody with clear reactivity with GP IX," the patterns were almost identical. Second, in other work from our laboratory, we have shown that GP Ibp is capable of forming partial complexes with both GP Iba and GP IX, but we were unable to demonstrate association of GP Iba with GP IX." The reactivity of SZI with CH0 alX cells, in which the expression of the two polypeptides has been amplified, suggests that no association of GP IX with GP Ib is needed to form the SZI epitope. However, one caveat is that we were unable to demonstrate convincingly expression of GP IX by itself (with either SZI or FMC25) in transient transfections of C H 0 cells with a GP IX cDNA and therefore have not definitively resolved the issue. A weak association may exist between GP Iba and GP IX that may be disrupted under even gentle detergent conditions.
The site recognized by SZI is likely to be close to, or identical to, the site recognized by a majority of drug-dependent antiplatelet antibodies in thrombocytopenic patients treated with quinine or quinidine. In addition to causing thrombocytopenia, autoantibodies in patients who take these medications may be associated with broader clinical syndromes that may include antibodies to other blood cells, causing cytopenias,".'" or even a condition that resembles adult hemolytic-uremic syndrome.".'" In all of these syndromes, the platelet antigen most frequently recognized by the drug-dependent antibodies resides on the GP Ib-IX complex. Kunicki et all" demonstrated that drug-dependent antisera from quinine-and quinidine-treated patients reacted in the presence of the offending medication with normal platelets, but not with Bernard-Soulier syndrome platelets, a finding that implicates one of the polypeptides missing in this disorder (the GP Ib-IX polypeptides and GP V) as the target antigen. Two groups later directly determined the involvement of GP Ib-IX as a target antigen by immunoprecipitating the complex with patient sera.'4.'' Berndt et all3 then demonstrated drug-dependent immunoprecipitation of GP Ib-IX and of the membrane-associated portion of the complex that remained after calpain treatment (which releases glycocalicin, a soluble peptide that represents the majority of the GP lba ectodomain) with serum from a patient with quinidineassociated thrombocytopenia. Platelet binding was also blocked by FMC25 (epitope on GP IX) and FMC25 (Fabh, which implicates GP IX as a possible antigen, despite the failure of the serum to precipitate GP IX. These findings suggest a similar conformational requirement for the drugdependent epitope as for the SZ1 epitope, and indicate that the epitopes for the two antibodies may be identical.
The best evidence that SZI is close to the site for drugdependent antibodies comes from the studies of Chong et a1,I5 who demonstrated that the sera of 12 patients with quinine/quinidine-induced thrombocytopenia bound to the GP Ib-IX complex-a reaction that was strongly inhibited by SZI and AKI (a monoclonal antibody that appears to bind the same epitope as SZI). FMC25 partially inhibited the binding of six of these sera to GP Ib-IX.
The current study strongly implicates GP IX as the polypeptide recognized by most of the platelet-reactive antibodies induced by quinine or quinidine. The results of preliminary work on several drug-dependent sera seem to verify this conclusion: their reactivity with the cell lines is identical to that of SZI (unpublished data). The cell lines described here should greatly facilitate further epitope-mapping studies. For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
